Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

High but Short-lived anti-SARS-CoV2 neutralizing, IgM, IgA, and IgG levels among mRNA-vaccinees compared to naturally-infected participants

Haissam Abou-Saleh, Bushra Y. Abo-Halawa, Salma Younes, Nadin Younes, Duaa W. Al-Sadeq, Farah M. Shurrab, Na Liu, Hamda Qotba, Nader Al-Dewik, Ahmad H. Ismail, Hadi M. Yassine, Laith J. Abu-Raddad, View ORCID ProfileGheyath K. Nasrallah
doi: https://doi.org/10.1101/2022.05.08.22274817
Haissam Abou-Saleh
1Biological Science Program, Department of Biological and Environmental Sciences, College of Arts and Science, Qatar University, Doha P.O. Box 2713, Qatar
2Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bushra Y. Abo-Halawa
1Biological Science Program, Department of Biological and Environmental Sciences, College of Arts and Science, Qatar University, Doha P.O. Box 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salma Younes
2Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadin Younes
2Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duaa W. Al-Sadeq
2Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
3College of Medicine, Q.U. Health, Qatar University, Doha P.O. Box 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farah M. Shurrab
2Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Na Liu
4Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hamda Qotba
5Department of Clinical Research, Primary Health Care Centers, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nader Al-Dewik
6Department of Pediatrics, Clinical and Metabolic Genetics, Hamad Medical Corporation, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmad H. Ismail
7Laboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hadi M. Yassine
2Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
8Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laith J. Abu-Raddad
9Infectious Disease Epidemiology Group, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar
10World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar
11Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gheyath K. Nasrallah
2Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
8Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gheyath K. Nasrallah
  • For correspondence: gheyath.nasrallah@qu.edu.qa
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

1. Abstract

Background Waning of protection against emerging SARS-CoV-2 variants by pre-existing antibodies elicited due to current vaccination or natural infection is a global concern. Whether this is due to waning of immunity to SARS-COV-2 remains unclear.

Aim We aimed to investigate dynamics of antibody isotype responses among vaccinated naïve (VN) and naturally infected (NI) individuals.

Methods We followed up antibody levels in COVID-19 mRNA-vaccinated subjects without prior infection (VN, n=100) at two phases: phase-I (P-I) at ∼1.4 and phase-II (P-II) at ∼5.3 months. Antibody levels were compared to those of unvaccinated and naturally infected subjects (NI, n=40) at ∼1.7 (P-1) and 5.2 (P-II) months post-infection. Neutralizing antibodies (NTAb), anti-S-RBD-IgG, -IgM, and anti-S-IgA isotypes were measured.

Results VN group produced significantly greater antibody responses (p<0.001) than NI group at P-I except for IgM. In VN group, a significant waning in antibody response was observed in all isotypes. There was about ∼ a 4-fold decline in NTAb levels (p<0.001), anti-S-RBD-IgG (∼5-folds, p<0.001), anti-S-RBD-IgM (∼6-folds, p<0.001), and anti-S1-IgA (2-folds, p<0.001). In NI group, a significant but less steady decline was notable in NTAb (∼1-folds, p<0.001), anti-S-RBD IgG (∼1-fold, p=0.005), and S-RBD-IgM (∼2-folds, p<0.001). Unlike VN group, NI group mounted a lasting anti-S1-IgA response with no significant decline. Anti-S1-IgA levels which were ∼3 folds higher in VN subjects compared to NI in P-1 (p<0.001), dropped to almost same levels, with no significant difference observed between the two groups in P-II.

Conclusion While double dose mRNA vaccination boosted antibody levels, this “boost” was relatively short-lived in vaccinated individuals.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was made possible by grant number UREP28-173-3-057 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was reviewed and approved by the Institutional Review Board at Qatar University (QU-IRB 1537-FBA/21).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 10, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
High but Short-lived anti-SARS-CoV2 neutralizing, IgM, IgA, and IgG levels among mRNA-vaccinees compared to naturally-infected participants
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
High but Short-lived anti-SARS-CoV2 neutralizing, IgM, IgA, and IgG levels among mRNA-vaccinees compared to naturally-infected participants
Haissam Abou-Saleh, Bushra Y. Abo-Halawa, Salma Younes, Nadin Younes, Duaa W. Al-Sadeq, Farah M. Shurrab, Na Liu, Hamda Qotba, Nader Al-Dewik, Ahmad H. Ismail, Hadi M. Yassine, Laith J. Abu-Raddad, Gheyath K. Nasrallah
medRxiv 2022.05.08.22274817; doi: https://doi.org/10.1101/2022.05.08.22274817
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
High but Short-lived anti-SARS-CoV2 neutralizing, IgM, IgA, and IgG levels among mRNA-vaccinees compared to naturally-infected participants
Haissam Abou-Saleh, Bushra Y. Abo-Halawa, Salma Younes, Nadin Younes, Duaa W. Al-Sadeq, Farah M. Shurrab, Na Liu, Hamda Qotba, Nader Al-Dewik, Ahmad H. Ismail, Hadi M. Yassine, Laith J. Abu-Raddad, Gheyath K. Nasrallah
medRxiv 2022.05.08.22274817; doi: https://doi.org/10.1101/2022.05.08.22274817

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Subject Areas
All Articles
  • Addiction Medicine (180)
  • Allergy and Immunology (435)
  • Anesthesia (99)
  • Cardiovascular Medicine (949)
  • Dentistry and Oral Medicine (178)
  • Dermatology (111)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (423)
  • Epidemiology (9014)
  • Forensic Medicine (4)
  • Gastroenterology (422)
  • Genetic and Genomic Medicine (1963)
  • Geriatric Medicine (191)
  • Health Economics (405)
  • Health Informatics (1332)
  • Health Policy (662)
  • Health Systems and Quality Improvement (522)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10831)
  • Intensive Care and Critical Care Medicine (576)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (223)
  • Neurology (1842)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (357)
  • Occupational and Environmental Health (470)
  • Oncology (1006)
  • Ophthalmology (299)
  • Orthopedics (111)
  • Otolaryngology (184)
  • Pain Medicine (126)
  • Palliative Medicine (45)
  • Pathology (267)
  • Pediatrics (583)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1910)
  • Public and Global Health (4137)
  • Radiology and Imaging (678)
  • Rehabilitation Medicine and Physical Therapy (370)
  • Respiratory Medicine (551)
  • Rheumatology (226)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (110)
  • Urology (82)